Johnson & Johnson (NYSE:JNJ) Shares Sold by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. cut its stake in Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 373,245 shares of the company’s stock after selling 8,357 shares during the period. Brown Brothers Harriman & Co.’s holdings in Johnson & Johnson were worth $54,553,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of JNJ. Tennessee Valley Asset Management Partners boosted its stake in shares of Johnson & Johnson by 48.6% in the 2nd quarter. Tennessee Valley Asset Management Partners now owns 2,969 shares of the company’s stock valued at $434,000 after buying an additional 971 shares during the period. Pine Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 1.9% in the second quarter. Pine Harbor Wealth Management LLC now owns 3,472 shares of the company’s stock worth $507,000 after acquiring an additional 64 shares during the last quarter. Plato Investment Management Ltd grew its holdings in Johnson & Johnson by 14.2% during the 2nd quarter. Plato Investment Management Ltd now owns 60,183 shares of the company’s stock worth $8,796,000 after acquiring an additional 7,475 shares in the last quarter. Poehling Capital Management INC. increased its position in shares of Johnson & Johnson by 88.6% in the 2nd quarter. Poehling Capital Management INC. now owns 5,804 shares of the company’s stock valued at $848,000 after purchasing an additional 2,727 shares during the last quarter. Finally, Stevard LLC raised its holdings in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Stevard LLC now owns 3,820 shares of the company’s stock valued at $558,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $165.52 on Monday. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a market capitalization of $398.45 billion, a price-to-earnings ratio of 10.32, a PEG ratio of 2.71 and a beta of 0.53. The company has a 50-day simple moving average of $159.55 and a 200-day simple moving average of $153.94. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the business earned $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, September 9th. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Morgan Stanley increased their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.